Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Mallinckrodt
Baxter
AstraZeneca

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Sodium iodide i-123 - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for sodium iodide i-123 and what is the scope of freedom to operate?

Sodium iodide i-123 is the generic ingredient in one branded drug marketed by Cardinal Health 418, Ge Healthcare, and Mallinkrodt Nuclear, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are one thousand four hundred and seventy-two drug master file entries for sodium iodide i-123. Two suppliers are listed for this compound.

Summary for sodium iodide i-123
Recent Clinical Trials for sodium iodide i-123

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alberta Cancer FoundationPhase 1
AHS Cancer Control AlbertaPhase 1
Oxford University Hospitals NHS TrustPhase 1/Phase 2

See all sodium iodide i-123 clinical trials

Synonyms for sodium iodide i-123
59216-98-7
61456-04-0
7681-82-5
AB1002290
AC1L1JWL
AC1Q1UK2
AC1Q1UKX
AC1Q1UKY
AC1Q1UKZ
AKOS015950612
AKOS016015354
ANW-36888
BCP22179
C14042
CAS-7681-82-5
Caswell No. 777
CHEBI:33167
CHEMBL1644695
CS-0013799
CTK3J2068
D04874
DB11119
DSSTox_CID_21125
DSSTox_GSID_41125
DSSTox_RID_79629
DTXSID2041125
EC 231-679-3
EINECS 231-679-3
EPA Pesticide Chemical Code 075702
F5WR8N145C
FT-0645131
FVAUCKIRQBBSSJ-UHFFFAOYSA-M
HSDB 750
I14-92366
iodosodium
Iodure de sodium
Ioduril
Jodid sodny
Jodid sodny [Czech]
K326
KB-60539
KS-000002MA
KSC492A6R
LS-145541
LS41973
MFCD00003532
MolPort-006-118-958
NAI
Natrii iodidum
natrium(131i)iodid
Natriumjodid
Natriumjodid [German]
NCGC00255631-01
NSC 77388
NSC-77388
NSC77388
RP21314
RTR-037750
S0564
SC-46812
sodium iodide
Sodium iodide (JP17/USP)
Sodium iodide (Na131I)
Sodium iodide (NaI)
Sodium iodide [USAN:JAN]
Sodium iodide [USP:JAN]
Sodium iodide solution
sodium iodide-
Sodium iodide, 99.999%, (trace metal basis), extra pure
Sodium iodide, 99+%, pure, anhydrous
SODIUM IODIDE, ACS
Sodium iodide, ACS grade
Sodium iodide, ACS reagent, anhydrous
Sodium iodide, Trace metals grade
sodium iodine-131(1-)
Sodium monoiodide
sodium-iodide
sodium(125i)iodide
sodiumiodide
Soiodin
Tox21_301379
TR-037750
TRA-0176291
UNII-F5WR8N145C
WLN: NA I

US Patents and Regulatory Information for sodium iodide i-123

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 SOLUTION;ORAL 017630-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Mallinkrodt Nuclear SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 071909-001 Feb 28, 1989 AA RX No No   Start Trial   Start Trial   Start Trial
Mallinkrodt Nuclear SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 071910-001 Feb 28, 1989 AA RX No No   Start Trial   Start Trial   Start Trial
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-002 May 27, 1982 AA RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 017630-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-003 May 27, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-001 May 27, 1982 AA RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Merck
Johnson and Johnson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.